Why Semiconductor Geography Is a Biosecurity Problem in Disguise

When analysts talk about semiconductor concentration risk, they tend to frame it as a defense-industrial problem: fighter jets, missile guidance, communications satellites. That framing is accurate but incomplete. The deeper vulnerability runs through the less-glamorous infrastructure that national security depends on, including the laboratory networks, genomic sequencing pipelines, and biosurveillance systems that constitute the early-warning layer for biological threats.

The basic geography is well-documented. A dominant share of the world's most advanced logic chips, those at or below the five-nanometer node, are fabricated in Taiwan, with a secondary concentration in South Korea. The equipment to make those chips is itself concentrated: lithography machines capable of extreme-ultraviolet processing are manufactured in the Netherlands by a single company, ASML, under export controls that are themselves a subject of ongoing geopolitical negotiation. This is a supply chain with very few redundant nodes.

What that means for biosecurity specifically is underappreciated. Consider the instrumentation stack that public health surveillance depends on. Next-generation sequencing platforms, the machines that identified SARS-CoV-2 variants in wastewater and clinical samples faster than traditional culturing methods could, are dense with application-specific integrated circuits and field-programmable gate arrays. Portable PCR platforms used in field settings during outbreak response depend on microcontroller families that are largely fabbed in the same constrained geography. The bioinformatics compute clusters that run pathogen phylogenetics are built on server-grade processors from the same upstream supply.

None of this means sequencers stop working tomorrow if a Taiwan Strait crisis degrades shipping lanes. The risk is not immediate severance; it is attrition. Equipment replacement cycles for laboratory instruments run roughly five to ten years. A sustained disruption to chip supply does not kill a sequencer in service; it kills the next generation of sequencers. Stockpiling finished chips for specific instruments is possible in theory but practically difficult, because the specific chip families used in a given instrument generation often reach end-of-life before the instrument does, and because procurement for public health infrastructure is rarely as forward-leaning as procurement for weapons systems.

The dual-use ambiguity here is real and worth flagging rather than flattening. The same fabrication capacity that supplies biodefense instrumentation also supplies consumer electronics, automotive systems, and data centers. Export controls designed to deny advanced chips to strategic competitors can, if designed without a public-health carve-out or a domestic-stockpile mechanism, create friction for the biosurveillance buyers governments actually want to protect. The 2022 CHIPS and Science Act in the United States represented a structural bet that domestic fabrication capacity could eventually reduce this dependence, but analysts who follow semiconductor economics assess, at moderate confidence, that meaningful domestic advanced-node capacity is a decade-plus project.

The intelligence-community dimension is worth a separate note. Biosurveillance depends on data pipelines, and data pipelines depend on network hardware, and network hardware is itself chip-constrained. An adversary attempting to degrade a competitor's early-warning capability for biological events has at least two vectors: the biological one, and the supply-chain one that leaves the detection layer underfunded and aging.

The conventional wisdom treats semiconductor policy and pandemic preparedness as separate bureaucratic lanes. The supply chain does not respect that organizational chart. Analysts who cover only one of these portfolios are, by design, missing the intersection.